Showing 7401-7410 of 9461 results for "".
- Analysis: Deucravacitinib Shows Sustained Efficacy and Safety Over Four Yearshttps://practicaldermatology.com/news/analysis-deucravacitinib-shows-sustained-efficacy-and-safety-over-four-years/2466961/A new analysis suggested that deucravacitinib showed acceptable safety and efficacy over the course of 4 years of treatment. The POETYK PSO-1 and PSO-2 trials, upon which the analysis was based, randomized patients in (1:2:1) to receive placebo, deucravacitinib 6 mg once daily (QD), or a
- Video-assisted Rhino-Septoplasty Technique Shows Validity: Studyhttps://practicaldermatology.com/news/video-assisted-rhino-septoplasty-technique-shows-validity-study/2466916/A new study suggests a video-guided rhino-septoplasty technique showed promise compared with more traditional techniques. "Conservative techniques have been developed in the field of rhinoplasty, focusing on limited tissue resection while emphasizing the reshaping of nasal structural elem
- Study Links Oral Contraceptives and CYP1B1 Variant to Alopecia Riskhttps://practicaldermatology.com/news/study-links-oral-contraceptives-and-cyp1b1-variant-alopecia-risk/2463230/Recent research published in JAMA Dermatology highlighted a potential linkage between the use of oral contraceptive pills (OCP) and the protective effect of a common missense variant in the CYP1B1 gene on the risk of developing frontal fibrosing alopecia (FFA). Researchers for the case-co
- Report: Advancements and Demand To Drive Aesthetic Medicine Market to $212.5 Billion by 2032https://practicaldermatology.com/news/advancements-and-demand-drive-aesthetic-medicine-market-2125-billion-2032/2463206/A new report forecasts growth in the aesthetic medicine market. Currently valued at US$ 75.6 billion, the report says that the value of the market is projected to reach US$ 212.5 billion by 2032, reflecting a robust compound annual growth rate of 12.17% from 2024 to 2032. The report attri
- Survey Shows Low Awareness, High Risk of Actinic Keratosis from Sun Exposurehttps://practicaldermatology.com/news/survey-shows-low-awareness-high-risk-actinic-keratosis-sun-exposure/2463197/A recent survey conducted by Almirall showed gaps in public awareness about actinic keratosis (AK) and the associated risks of sun exposure. The survey, which included more than 2,500 participants aged 35 and older from Spain, Germany, Italy, the United Kingdom, and the United States, rev
- Alma Unveils Versatile Aesthetic Workstation and Smart Skin Analysis Systemhttps://practicaldermatology.com/news/alma-unveils-versatile-aesthetic-workstation-and-smart-skin-analysis-system/2463172/Energy-based device manufacturer Alma has introduced Alma Harmony and Alma IQ. Alma Harmony is the latest version of the company's multi-technology aesthetics workstation and is available for sale in the U.S. This system, according to a press release, builds on a 20-year legacy and is FDA
- Benign Nail Condition Linked to Cancer Riskhttps://practicaldermatology.com/news/benign-nail-condition-linked-cancer-risk/2463171/The presence of a benign nail abnormality may lead to the diagnosis of a rare inherited disorder that increases the risk of developing cancerous tumors of the skin, eyes, kidneys and the tissue that lines the chest and abdomen (eg, the mesothelium), according to scientists at the National Institu
- Antihypertensive Drugs Linked to Increased Eczema in Elderlyhttps://practicaldermatology.com/news/antihypertensive-drugs-linked-increased-eczema-elderly/2463140/New research suggests that increased use of antihypertensive medications is associated with an increase in eczematous dermatitis. Researchers conducted a longitudinal cohort study in a population-based sample from primary care practices in The Health Improvement Network in the United Kingd
- Humira Biosimilar Simlandi Now Available in the UShttps://practicaldermatology.com/news/humira-biosimilar-simlandi-now-available-us/2463126/Teva Pharmaceuticals and Alvotech announced the availability of Simlandi (adalimumab-ryvk) injection in the US as an interchangeable biosimilar to Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as adult rheumatoid arthritis, j
- Roflumilast Foam Aligns with Industry Standards for Seborrheic Dermatitis Care: Studyhttps://practicaldermatology.com/news/roflumilast-foam-aligns-industry-standards-sd-care-study/2463119/A recent study published in the Journal of Clinical and Aesthetic Dermatology supports the approved formulation of roflumilast foam, noting that its alignment with beauty industry standards and exclusion of harmful ingredients is important for the confidence of practitioners using the tr